Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication

Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication

Fibroblast growth factor 21 (FGF-21), previously recognized as a marker of liver damage and a potential drug target in non-alcoholic fatty liver disease (NAFLD), has unclear implications in hepatitis C virus (HCV) infections. This study aimed to investigate the relationship between FGF-21 levels and...

Full description

Bibliographic Details
Main Authors:	Filippo Biagi, Francesco Carlomagno, Martina Carbone, Roberta Veralli, Umberto Vespasiani-Gentilucci, Elisabetta Riva, Silvia Manfrini, Dario Tuccinardi, Adriano De Santis, Lucio Gnessi, Mikiko Watanabe
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	Metabolites
Subjects:	cirrhosis DAAs FGF-21 HCV NAFLD NASH
Online Access:	https://www.mdpi.com/2218-1989/13/11/1119

Similar Items

The impact of HCV eradication using interferon-free direct acting antivirals on bone-mineral, anemia parameters and peripheral insulin resistance in hepatitis c-infected Egyptian hemodialysis cohort
by: Mahmoud M. Elnokeety, et al.
Published: (2023-10-01)

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
by: Chung-Feng Huang, et al.
Published: (2024-10-01)

HCV eradication in people living with HIV: the final countdown?
by: A. De Vito, et al.
Published: (2021-02-01)

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
by: Nahed Mohammed Hawsawi, et al.
Published: (2023-01-01)

Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
by: Amr Maged Mahmoud Rasheed, et al.
Published: (2025-02-01)

Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series
by: Fabian Patauner, et al.
Published: (2022-07-01)

Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication
by: Chung‐Feng Huang, et al.
Published: (2020-11-01)

Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
by: Alexandra S. Aaldijk, et al.
Published: (2023-05-01)

Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
by: Xiaoxue Long, et al.
Published: (2021-12-01)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01)

Recognition of 7 genes signature (Cirrhosis Risk Score) in the diagnosed non-responders to DAAs therapy by intra-PBMCs nested HCV RNA PCR
by: Al-Shazly Gaber Mohamed Galal, et al.
Published: (2023-08-01)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
by: Pinchera B, et al.
Published: (2023-02-01)

Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma
by: Xiaoyu Liu, et al.
Published: (2022-08-01)

Effects of homocysteine on nonalcoholic fatty liver related disease: A mendelian randomization study
by: Pengcheng Chen, et al.
Published: (2022-12-01)

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
by: Myriam Alexander, et al.
Published: (2019-05-01)

Peripheral Neuropathy in Patients with Hepatitis C Infection—Reversibility after HCV Eradication: A Single Center Study
by: Theodoros Androutsakos, et al.
Published: (2024-03-01)

Hepatitis C Elimination in Egypt: Story of Success
by: Asmaa Gomaa, et al.
Published: (2024-08-01)

Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients
by: Mariantonietta Di Stefano, et al.
Published: (2021-09-01)

Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection
by: Chih-Hsun Yi, et al.
Published: (2022-08-01)

Prediction and surveillance of de novo HCC in patients with compensated advanced chronic liver disease after hepatitis C virus eradication with direct antiviral agents
by: Ashraf Elbahrawy, et al.
Published: (2023-10-01)

The predictive role of the platelet-to-lymphocyte ratio for the risk of non-alcoholic fatty liver disease and cirrhosis: a nationwide cross-sectional study
by: Cheng Yan, et al.
Published: (2024-07-01)

From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
by: Ahmed M. Samy, et al.
Published: (2024-05-01)

The role of FGF21 and its analogs on liver associated diseases
by: Kimia Falamarzi, et al.
Published: (2022-11-01)

Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
by: Seren M. Gedallovich, et al.
Published: (2024-10-01)

PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
by: Kalliopi Zachou, et al.
Published: (2017-01-01)

Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”
by: Ming-Ying Lu, et al.
Published: (2024-04-01)

The Role of RASs /RVs in the Current Management of HCV
by: Konstantinos Malandris, et al.
Published: (2021-10-01)

Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan – A multi-center collaborative care model
by: Ching-Chu Lo, et al.
Published: (2023-08-01)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
by: Jian Zhang, et al.
Published: (2019-07-01)

2020 Taiwan consensus statement on the management of hepatitis C: part (I) general populationRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendations
by: Ming-Lung Yu, et al.
Published: (2020-06-01)

Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
by: Irene Pericot-Valverde, et al.
Published: (2020-12-01)

Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study
by: Mekky MA, et al.
Published: (2019-01-01)

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
by: Beatriz Álvarez, et al.
Published: (2020-06-01)

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
by: Abdul Haseeb Hasan, et al.
Published: (2025-01-01)

Gut Microbiome in the Progression of NAFLD, NASH and Cirrhosis, and Its Connection with Biotics: A Bibliometric Study Using Dimensions Scientific Research Database
by: Salvatore Pezzino, et al.
Published: (2023-04-01)

Estimating the cost of illness of non‐alcoholic fatty liver disease in Bangladesh
by: Shahinul Alam, et al.
Published: (2023-09-01)

Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease
by: Jingjing Jiao, et al.
Published: (2023-02-01)

Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis
by: Tanat Yongpisarn, et al.
Published: (2022-12-01)

Research perspectives on the regulation and physiological functions of FGF21 and its association with NAFLD
by: Takeshi eInagaki
Published: (2015-09-01)

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
by: Lucy Meunier, et al.
Published: (2022-12-01)